ASCO Guideline Update | Breast Cancer & CV Disease | Cleared: GDX012June 21, 2021 | Oncology Endocrinology, Diabetes, Metabolism Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update An update from the original ASCO guideline on this topic published in 2012, 60 studies, primarily retrospective, were included in the review. New to this version of the guideline, the Panel offers recommendations on approved doses of immunotherapy and targeted therapies that can be offered to obese patients with cancer. Read full article Cardiology Association of Breast Cancer Irradiation With Cardiac Toxic Effects In this JAMA Oncology Narrative Review, the authors attempt to discover whether cardiovascular risks may be associated with the multimodal approach, including systemic therapies and breast radiotherapy (RT), in treating breast cancer patients. Although recent advancements in breast cancer treatment have led to a decrease in mortality rates, the prevalence of survivors with a potentially high CV disease risk has increased. Read full article Hematology FDA Clears IND Application for Gamma Delta T-Cell Therapy The investigational new drug (IND) application is for GDX012, which also received an FDA orphan drug designation for the treatment of acute myeloid leukemia (AML). The drug’s manufacturer, GammaDelta Therapeutics, is developing the T-cell platform in partnership with Takeda and will initiate a phase I study in late 2021 that will evaluate the treatment’s safety and activity in patients with measurable residual disease-positive AML. Read full article
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS